Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 13, 2013 - Issue 7
Submit an article Journal homepage
154
Views
8
CrossRef citations to date
0
Altmetric
Theme: Gynecological Cancer - Review

Prevention, identification and treatment of vulvar squamous (pre)malignancies: a review focusing on quality of care

Loes CG van den Einden Department of Obstetrics and Gynaecology, Radboud University Medical Centre, Nijmegen, The Netherlands. [email protected]; Department of Obstetrics and Gynaecology, Radboud University Medical Centre, Nijmegen, The Netherlands. [email protected]
,
Irene AM van der Avoort Department of Obstetrics and Gynaecology, Radboud University Medical Centre, Nijmegen, The Netherlands; Department of Obstetrics and Gynaecology, Catherina Hospital, Eindhoven, The Netherlands; Department of Obstetrics and Gynaecology, Radboud University Medical Centre, Nijmegen, The Netherlands; Department of Obstetrics and Gynaecology, Catherina Hospital, Eindhoven, The Netherlands
&
Joanne A de Hullu Department of Obstetrics and Gynaecology, Radboud University Medical Centre, Nijmegen, The Netherlands; Department of Obstetrics and Gynaecology, Radboud University Medical Centre, Nijmegen, The Netherlands
Pages 845-859 | Published online: 10 Jan 2014

References

  • Sankaranarayanan R, Ferlay J. Worldwide burden of gynaecological cancer: the size of the problem. Best Pract. Res. Clin. Obstet. Gynaecol. 20(2), 207–225 (2006).
  • van den Einden LC, Aben KK, Massuger LF, van Spronsen DJ, de Hullu JA. Successful centralisation of patients with vulvar carcinoma: a population-based study in The Netherlands. Eur. J. Cancer 48(13), 1997–2003 (2012).
  • van der Avoort IA, Shirango H, Hoevenaars BM et al. Vulvar squamous cell carcinoma is a multifactorial disease following two separate and independent pathways. Int. J. Gynecol. Pathol. 25(1), 22–29 (2006).
  • van de Nieuwenhof HP, Bulten J, Hollema H et al. Differentiated vulvar intraepithelial neoplasia is often found in lesions, previously diagnosed as lichen sclerosus, which have progressed to vulvar squamous cell carcinoma. Modern Pathol. 24(2), 297–305 (2011).
  • Yang B, Hart WR. Vulvar intraepithelial neoplasia of the simplex (differentiated) type: a clinicopathologic study including analysis of HPV and p53 expression. Am. J. Surg. Pathol. 24(3), 429–441 (2000).
  • Leibowitch M, Neill S, Pelisse M, Moyal-Baracco M. The epithelial changes associated with squamous cell carcinoma of the vulva: a review of the clinical, histological and viral findings in 78 women. Br. J. Obstet. Gynaecol. 97(12), 1135–1139 (1990).
  • Carli P, Cattaneo A, De Magnis A, Biggeri A, Taddei G, Giannotti B. Squamous cell carcinoma arising in vulval lichen sclerosus: a longitudinal cohort study. Eur. J. Cancer Prev. 4(6), 491–495 (1995).
  • Medicine Io. Crossing the Quality Chasm. A New Health System for the 21st Century. National Academy Press, Washington, DC, USA (2001).
  • Bodelon C, Madeleine MM, Voigt LF, Weiss NS. Is the incidence of invasive vulvar cancer increasing in the United States? Cancer Causes Control 20(9), 1779–1782 (2009).
  • Baandrup L, Varbo A, Munk C, Johansen C, Frisch M, Kjaer SK. In situ and invasive squamous cell carcinoma of the vulva in Denmark 1978–2007 – a nationwide population-based study. Gynecol. Oncol. 122(1), 45–49 (2011).
  • Judson PL, Habermann EB, Baxter NN, Durham SB, Virnig BA. Trends in the incidence of invasive and in situ vulvar carcinoma. Obstet. Gynecol. 107(5), 1018–1022 (2006).
  • De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int. J. Cancer 124(7), 1626–1636 (2009).
  • van de Nieuwenhof HP, van Kempen LC, de Hullu JA et al. The etiologic role of HPV in vulvar squamous cell carcinoma fine tuned. Cancer Epidemiol. 18(7), 2061–2067 (2009).
  • Pinto AP, Lin MC, Sheets EE, Muto MG, Sun D, Crum CP. Allelic imbalance in lichen sclerosus, hyperplasia, and intraepithelial neoplasia of the vulva. Gynecol. Oncol. 77(1), 171–176 (2000).
  • Liegl B, Regauer S. p53 immunostaining in lichen sclerosus is related to ischaemic stress and is not a marker of differentiated vulvar intraepithelial neoplasia (d-VIN). Histopathology 48(3), 268–274 (2006).
  • Hoevenaars BM, van der Avoort IA, de Wilde PC et al. A panel of p16(INK4A), MIB1 and p53 proteins can distinguish between the 2 pathways leading to vulvar squamous cell carcinoma. Int. J. Cancer 123(12), 2767–2773 (2008).
  • zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer 2(5), 342–350 (2002).
  • De Hullu JA, Hollema H, Lolkema S et al. Vulvar carcinoma. The price of less radical surgery. Cancer 95(11), 2331–2338 (2002).
  • Homesley HD, Bundy BN, Sedlis A, Adcock L. Radiation therapy versus pelvic node resection for carcinoma of the vulva with positive groin nodes. Obstet. Gynecol. 68(6), 733–740 (1986).
  • Selman TJ, Luesley DM, Acheson N, Khan KS, Mann CH. A systematic review of the accuracy of diagnostic tests for inguinal lymph node status in vulvar cancer. Gynecol. Oncol. 99(1), 206–214 (2005).
  • Oonk MH, van Hemel BM, Hollema H et al. Size of sentinel-node metastasis and chances of non-sentinel-node involvement and survival in early stage vulvar cancer: results from GROINSS-V, a multicentre observational study. Lancet Oncol. 11(7), 646–652 (2010).
  • Hoffman MS. Squamous-cell carcinoma of the vulva: locally advanced disease. Best Pract. Res. Clin. Obstet. Gynaecol. 17(4), 635–647 (2003).
  • Bellati F, Angioli R, Manci N et al. Single agent cisplatin chemotherapy in surgically resected vulvar cancer patients with multiple inguinal lymph node metastases. Gynecol. Oncol. 96(1), 227–231 (2005).
  • Montana GS, Thomas GM, Moore DH et al. Preoperative chemo-radiation for carcinoma of the vulva with N2/N3 nodes: a gynecologic oncology group study. Int. J. Radiat. Oncol. Biol. Phys. 48(4), 1007–1013 (2000).
  • de Wilde RF, Besselink MG, van der Tweel I et al.; Dutch Pancreatic Cancer Group. Impact of nationwide centralization of pancreaticoduodenectomy on hospital mortality. Br. J. Surg. 99(3), 404–410 (2012).
  • Van der Zee AG, Oonk MH, De Hullu JA et al. Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. J. Clin. Oncol. 26(6), 884–889 (2008).
  • Woelber L, Mahner S, Voelker K et al. Clinicopathological prognostic factors and patterns of recurrence in vulvar cancer. Anticancer Res. 29(2), 545–552 (2009).
  • van der Steen S, de Nieuwenhof HP, Massuger L, Bulten J, de Hullu JA. New FIGO staging system of vulvar cancer indeed provides a better reflection of prognosis. Gynecol. Oncol. 119(3), 520–525 (2010).
  • Tabbaa ZM, Gonzalez J, Sznurkowski JJ, Weaver AL, Mariani A, Cliby WA. Impact of the new FIGO 2009 staging classification for vulvar cancer on prognosis and stage distribution. Gynecol. Oncol. 127(1), 147–152 (2012).
  • Gadducci A, Tana R, Barsotti C, Guerrieri ME, Genazzani AR. Clinico-pathological and biological prognostic variables in squamous cell carcinoma of the vulva. Crit. Rev. Oncol. Hematol. 83(1), 71–83 (2012).
  • Del Pino M, Rodriguez-Carunchio L, Ordi J. Pathways of vulvar intraepithelial neoplasia and squamous cell carcinoma. Histopathology 62(1), 161–175 (2013).
  • Sideri M, Jones RW, Wilkinson EJ et al. Squamous vulvar intraepithelial neoplasia: 2004 modified terminology, ISSVD Vulvar Oncology Subcommittee. J. Reprod. Med. 50(11), 807–810 (2005).
  • Preti M, Van Seters M, Sideri M, Van Beurden M. Squamous vulvar intraepithelial neoplasia. Clin. Obstet. Gynecol. 48(4), 845–861 (2005).
  • Scurry J, Wilkinson EJ. Review of terminology of precursors of vulvar squamous cell carcinoma. J. Low. Genit. Tract Dis. 10(3), 161–169 (2006).
  • Darragh TM, Colgan TJ, Thomas Cox J et al.; Members of the LAST Project Work Groups. The Lower Anogenital Squamous Terminology Standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Int. J. Gynecol. Pathol. 32(1), 76–115 (2013).
  • Wallace HJ. Lichen sclerosus et atrophicus. Trans. St. Johns. Hosp. Dermatol. Soc. 57(1), 9–30 (1971).
  • Fischer G, Spurrett B, Fischer A. The chronically symptomatic vulva: aetiology and management. Br. J. Obstet. Gynaecol. 102(10), 773–779 (1995).
  • Goldstein AT, Marinoff SC, Christopher K, Srodon M. Prevalence of vulvar lichen sclerosus in a general gynecology practice. J. Reprod. Med. 50(7), 477–480 (2005).
  • Wood PL, Bevan T. Lesson of the week child sexual abuse enquiries and unrecognised vulval lichen sclerosus et atrophicus. BMJ 319(7214), 899–900 (1999).
  • Longinotti M, Schieffer YM, Kaufman RH. Lichen sclerosus involving the vagina. Obstet. Gynecol. 106(5 Pt 2), 1217–1219 (2005).
  • Wilkinson EJ, Massoll NA. Benign disease of the vulva. In: Blaustein’s Pathology of the Female Genital Tract. Kurman RJ (Ed.). Springer, NY, USA, 1–55 (2011).
  • Neill SM, Lewis FM, Tatnall FM, Cox NH; British Association of Dermatologists. British Association of Dermatologists’ guidelines for the management of lichen sclerosus 2010. Br. J. Dermatol. 163(4), 672–682 (2010).
  • Smith YR, Haefner HK. Vulvar lichen sclerosus: pathophysiology and treatment. Am. J. Clin. Dermatol. 5(2), 105–125 (2004).
  • Virgili A, Minghetti S, Borghi A, Corazza M. Proactive maintenance therapy with a topical corticosteroid for vulvar lichen sclerosus: preliminary results of a randomized study. Br. J. Dermatol. doi:10.1111/bjd.12273 (2013) (Epub ahead of print).
  • Funaro D. Lichen sclerosus: a review and practical approach. Dermatol. Ther. 17(1), 28–37 (2004).
  • Powell JJ, Wojnarowska F. Lichen sclerosus. Lancet 353(9166), 1777–1783 (1999).
  • Simonart T, Lahaye M, Simonart JM. Vulvar lichen sclerosus: effect of maintenance treatment with a moisturizer on the course of the disease. Menopause 15(1), 74–77 (2008).
  • Maclean AB. Vulval cancer: prevention and screening. Best Pract. Res. Clin. Obstet. Gynaecol. 20(2), 379–395 (2006).
  • Kagie MJ, Kenter GG, Hermans J, Trimbos JB, Fleuren GJ. The relevance of various vulvar epithelial changes in the early detection of squamous cell carcinoma of the vulva. Int. J. Gynecol. Cancer 7(1), 50–57 (1997).
  • Jones RW, Sadler L, Grant S, Whineray J, Exeter M, Rowan D. Clinically identifying women with vulvar lichen sclerosus at increased risk of squamous cell carcinoma: a case–control study. J. Reprod. Med. 49(10), 808–811 (2004).
  • Cooper SM, Gao XH, Powell JJ, Wojnarowska F. Does treatment of vulvar lichen sclerosus influence its prognosis? Arch. Dermatol. 140(6), 702–706 (2004).
  • Scurry J. Does lichen sclerosus play a central role in the pathogenesis of human papillomavirus negative vulvar squamous cell carcinoma? The itch-scratch-lichen sclerosus hypothesis. Int. J. Gynecol. Cancer 9(2), 89–97 (1999).
  • Val I, Almeida G. An overview of lichen sclerosus. Clin. Obstet. Gynecol. 48(4), 808–817 (2005).
  • van de Nieuwenhof HP, Massuger LF, van der Avoort IA et al. Vulvar squamous cell carcinoma development after diagnosis of VIN increases with age. Eur. J. Cancer 45(5), 851–856 (2009).
  • Hart WR. Vulvar intraepithelial neoplasia: historical aspects and current status. Int. J. Gynecol. Pathol. 20(1), 16–30 (2001).
  • Scurry J, Campion M, Scurry B, Kim SN, Hacker N. Pathologic audit of 164 consecutive cases of vulvar intraepithelial neoplasia. Int. J. Gynecol. Pathol. 25(2), 176–181 (2006).
  • van den Einden LC, de Hullu JA, Massuger LF et al. Interobserver variability and the effect of education in the histopathological diagnosis of differentiated vulvar intraepithelial neoplasia. Mod. Pathol. doi:10.1038/modpathol.2012.235 (2013) (Epub ahead of print).
  • Mulvany NJ, Allen DG. Differentiated intraepithelial neoplasia of the vulva. Int. J. Gynecol. Pathol. 27(1), 125–135 (2008).
  • Kaufman RH. Intraepithelial neoplasia of the vulva. Gynecol. Oncol. 56(1), 8–21 (1995).
  • McNally OM, Mulvany NJ, Pagano R, Quinn MA, Rome RM. VIN 3: a clinicopathologic review. Int. J. Gynecol. Cancer 12(5), 490–495 (2002).
  • de Bie RP, van de Nieuwenhof HP, Bekkers RL et al. Patients with usual vulvar intraepithelial neoplasia-related vulvar cancer have an increased risk of cervical abnormalities. Br. J. Cancer 101(1), 27–31 (2009).
  • Wilkinson EJ. Premalignant and malignant tumors. In: Blaustein’s pathology of the female genital tract. Kurman RJ (Ed.). Springer, New York, NY, USA 55–103 (2011).
  • Pepas L, Kaushik S, Bryant A, Nordin A, Dickinson HO. Medical interventions for high grade vulval intraepithelial neoplasia. Cochrane Database Syst. Rev. 4, CD007924 (2011).
  • Andreasson B, Bock JE. Intraepithelial neoplasia in the vulvar region. Gynecol. Oncol. 21(3), 300–305 (1985).
  • van Seters M, van Beurden M, de Craen AJ. Is the assumed natural history of vulvar intraepithelial neoplasia III based on enough evidence? A systematic review of 3322 published patients. Gynecol. Oncol. 97(2), 645–651 (2005).
  • Wallbillich JJ, Rhodes HE, Milbourne AM et al. Vulvar intraepithelial neoplasia (VIN 2/3): comparing clinical outcomes and evaluating risk factors for recurrence. Gynecol. Oncol. 127(2), 312–315 (2012).
  • Stanley MA. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin. Exp. Dermatol. 27(7), 571–577 (2002).
  • van Seters M, Fons G, van Beurden M. Imiquimod in the treatment of multifocal vulvar intraepithelial neoplasia 2/3. Results of a pilot study. J. Reprod. Med. 47(9), 701–705 (2002).
  • Terlou A, van Seters M, Ewing PC et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: seven years median follow-up of a randomized clinical trial. Gynecol. Oncol. 121(1), 157–162 (2011).
  • van Seters M, van Beurden M, ten Kate FJ et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. N. Engl. J. Med. 358(14), 1465–1473 (2008).
  • Mathiesen O, Buus SK, Cramers M. Topical imiquimod can reverse vulvar intraepithelial neoplasia: a randomised, double-blinded study. Gynecol. Oncol. 107(2), 219–222 (2007).
  • Todd RW, Steele JC, Etherington I, Luesley DM. Detection of CD8+ T cell responses to human papillomavirus type 16 antigens in women using imiquimod as a treatment for high-grade vulval intraepithelial neoplasia. Gynecol. Oncol. 92(1), 167–174 (2004).
  • van Beurden M, van Der Vange N, ten Kate FJ, de Craen AJ, Schilthuis MS, Lammes FB. Restricted surgical management of vulvar intraepithelial neoplasia 3: Focus on exclusion of invasion and on relief of symptoms. Int. J. Gynecol. Cancer 8(1), 73–77 (1998).
  • Jones RW, Rowan DM, Stewart AW. Vulvar intraepithelial neoplasia: aspects of the natural history and outcome in 405 women. Obstet. Gynecol. 106(6), 1319–1326 (2005).
  • Modesitt SC, Waters AB, Walton L, Fowler WC Jr, Van Le L. Vulvar intraepithelial neoplasia III: occult cancer and the impact of margin status on recurrence. Obstet. Gynecol. 92(6), 962–966 (1998).
  • Wehbe-Alamah H, Kornblau BL, Haderer J, Erickson J. Silent no more! The lived experiences of women with lichen sclerosis. J. Am. Acad. Nurse Pract. 24(8), 499–505 (2012).
  • Van de Nieuwenhof HP, Meeuwis KA, Nieboer TE, Vergeer MC, Massuger LF, De Hullu JA. The effect of vulvar lichen sclerosus on quality of life and sexual functioning. J. Psychosom. Obstet. Gynecol. 31(4), 279–284 (2010).
  • Aerts L, Enzlin P, Vergote I, Verhaeghe J, Poppe W, Amant F. Sexual, psychological, and relational functioning in women after surgical treatment for vulvar malignancy: a literature review. J. Sex. Med. 9(2), 361–371 (2012).
  • Jefferies H, Clifford C. A literature review of the impact of a diagnosis of cancer of the vulva and surgical treatment. J. Clin. Nurs. 20(21–22), 3128–3142 (2011).
  • Lansdorp CA, van den Hondel KE, Korfage IJ, van Gestel MJ, van der Meijden WI. Quality of life in Dutch women with lichen sclerosus. Br. J. Dermatol. 168(4), 787–793 (2013).
  • Vandborg MP, Christensen RD, Kragstrup J et al. Reasons for diagnostic delay in gynecological malignancies. Int. J. Gynecol. Cancer 21(6), 967–974 (2011).
  • Fons G, Burger MP, Ten Kate FJ, van der Velden J. Tumour growth in waiting time before therapy in patients with squamous cell cancer of the vulva. Presented at: 11th meeting of the International Gynecologic Cancer Society. Santa Monica, CA, USA, 14–18 October 2006.
  • Nunns D, Mandal D. The chronically symptomatic vulva: prevalence in primary health care. Genitourin. Med. 72(5), 343–344 (1996).
  • Jones RW, Scurry J, Neill S, MacLean AB. Guidelines for the follow-up of women with vulvar lichen sclerosus in specialist clinics. Am. J. Obstet. Gynecol. 198(5), 496.e1–496.e3 (2008).
  • BIBBY AV. Carcinoma of the vulva; a review of 71 cases. J. Obstet. Gynaecol. Br. Emp. 64(2), 263–266 (1957).
  • Raspollini MR, Asirelli G, Moncini D, Taddei GL. A comparative analysis of lichen sclerosus of the vulva and lichen sclerosus that evolves to vulvar squamous cell carcinoma. Am. J. Obstet. Gynecol. 197(6), 592.e1–592.e5 (2007).
  • van der Avoort IA, van de Nieuwenhof HP, Otte-Höller I et al. High levels of p53 expression correlate with DNA aneuploidy in (pre)malignancies of the vulva. Hum. Pathol. 41(10), 1475–1485 (2010).
  • Denny LA, Franceschi S, de Sanjosé S, Heard I, Moscicki AB, Palefsky J. Human papillomavirus, human immunodeficiency virus and immunosuppression. Vaccine 30(Suppl. 5), F168–F174 (2012).
  • Jamieson DJ, Paramsothy P, Cu-Uvin S, Duerr A; HIV Epidemiology Research Study Group. Vulvar, vaginal, and perianal intraepithelial neoplasia in women with or at risk for human immunodeficiency virus. Obstet. Gynecol. 107(5), 1023–1028 (2006).
  • Conley LJ, Ellerbrock TV, Bush TJ, Chiasson MA, Sawo D, Wright TC. HIV-1 infection and risk of vulvovaginal and perianal condylomata acuminata and intraepithelial neoplasia: a prospective cohort study. Lancet 359(9301), 108–113 (2002).
  • Clifford GM, Gonçalves MA, Franceschi S; HPV and HIV Study Group. Human papillomavirus types among women infected with HIV: a meta-analysis. AIDS 20(18), 2337–2344 (2006).
  • Forman D, de Martel C, Lacey CJ et al. Global burden of human papillomavirus and related diseases. Vaccine 30(Suppl. 5), F12–F23 (2012).
  • Meeuwis KA, Melchers WJ, Bouten H et al. Anogenital malignancies in women after renal transplantation over 40 years in a single center. Transplantation 93(9), 914–922 (2012).
  • van den Reek JM, van Lümig PP, Kievit W et al. Effectiveness of adalimumab dose escalation, combination therapy of adalimumab with methotrexate, or both in patients with psoriasis in daily practice. J. Dermatolog. Treat. doi:10.3109/09546634.2012.751483 (2013) (Epub ahead of print).
  • van Lümig PP, Driessen RJ, Berends MA, Boezeman JB, van de Kerkhof PC, de Jong EM. Safety of treatment with biologics for psoriasis in daily practice: 5-year data. J. Eur. Acad. Dermatol. Venereol. 26(3), 283–291 (2012).
  • Setshedi M, Epstein D, Winter TA, Myer L, Watermeyer G, Hift R. Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: a cohort study. J. Gastroenterol. Hepatol. 27(2), 385–389 (2012).
  • Transplantation EEGoR. European best practice guidelines for renal transplantation. Section IV: long-term management of the transplant recipient. Nephrol. Dialysis Transplant. 17(Suppl. 4), 1–67 (2002).
  • Centers for Disease Control and Prevention. Guidelines for prevention and treatment of oppertunistic infections in HIV-infected adults and adolescents. In: Morbidity and Mortality Weekly Report. Atlanta, USA, 70–71 (2009).
  • Bae-Jump VL, Bauer M, Van Le L. Cytological evaluation correlates poorly with histological diagnosis of vulvar neoplasias. J. Low. Genit. Tract Dis. 11(1), 8–11 (2007).
  • van den Einden LC, Grefte JM, van der Avoort IA et al. Cytology of the vulva: feasibility and preliminary results of a new brush. Br. J. Cancer 106(2), 269–273 (2012).
  • Jiménez-Ayala M, Jiménez-Ayala B. Terminology for vulvar cytology based on the Bethesda System. Acta Cytol. 46(4), 645–650 (2002).
  • Levine TS, Rolfe KJ, Crow J et al. The use of cytospin monolayer technique in the cytological diagnosis of vulval and anal disease. Cytopathology 12(5), 297–305 (2001).
  • Nauth HF, Schilke E. Cytology of the exfoliative layer in normal and diseased vulvar skin: correlation with histology. Acta Cytol. 26(3), 269–283 (1982).
  • Dennerstein G. Vulvar cytology: useful or not? J. Low. Genit. Tract Dis. 13(3), 192; author reply 192 (2009).
  • Jonsson M, Karlsson R, Evander M, Gustavsson A, Rylander E, Wadell G. Acetowhitening of the cervix and vulva as a predictor of subclinical human papillomavirus infection: sensitivity and specificity in a population-based study. Obstet. Gynecol. 90(5), 744–747 (1997).
  • Maggino T, Landoni F, Sartori E et al. Patterns of recurrence in patients with squamous cell carcinoma of the vulva. A multicenter CTF Study. Cancer 89(1), 116–122 (2000).
  • Oonk MH, de Hullu JA, Hollema H et al. The value of routine follow-up in patients treated for carcinoma of the vulva. Cancer 98(12), 2624–2629 (2003).
  • Nordin A, Mohammed KA, Naik R, de Barros Lopes A, Monaghan J. Does long-term follow-up have a role for node negative squamous carcinoma of the vulva? The Gateshead experience. Eur. J. Gynaecol. Oncol. 22(1), 36–39 (2001).
  • Birch HW, Collins JH. The vulvar clinic: a teaching and research project. South. Med. J. 53, 473–477 (1960).
  • Paavonen J, Naud P, Salmerón J et al.; HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374(9686), 301–314 (2009).
  • Joura EA, Leodolter S, Hernandez-Avila M et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 369(9574), 1693–1702 (2007).
  • Joura EA, Garland SM, Paavonen J et al.; FUTURE I and II Study Group. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ 344, e1401 (2012).
  • Kenter GG, Welters MJ, Valentijn AR et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med. 361(19), 1838–1847 (2009).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.